Acadia CFO Mark Schneyer sells $587k in company stock

Mark C. Schneyer, Executive Vice President and Chief Financial Officer of ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD), sold a total of $587,242 worth of company common stock over two days in early August. The transactions occurred on August 5 and August 6, 2026.

Mr. Schneyer disposed of a total of 20,141 shares of common stock. These sales took place at prices ranging from $29.00 to $29.3375 per share. The transactions were executed pursuant to a Rule 10b5-1 trading plan, which Mr. Schneyer adopted on May 19, 2025.

Concurrently with some of the sales, Mr. Schneyer also acquired 20,141 shares of ACADIA PHARMACEUTICALS common stock by exercising stock options. These options were exercised at a price of $17.84 per share, totaling $359,315. The stock options had a vesting schedule where 25% of the shares became exercisable on March 25, 2025, with the remainder vesting in 36 equal monthly installments thereafter.

Following these reported transactions, Mr. Schneyer directly holds 67,828 shares of ACADIA PHARMACEUTICALS common stock. This figure includes 1,683 shares acquired earlier on May 15, 2026, through an employee stock purchase plan.The timing of these sales coincides with ACADIA trading near its 52-week high of $29.48, with the stock delivering a 12.91% return over the past week. According to InvestingPro analysis, ACADIA appears undervalued at current levels, with the stock trading below its Fair Value. The company maintains a "GREAT" financial health score and a P/E ratio of 12.94. Investors seeking deeper insights can access ACADIA’s comprehensive Pro Research Report, one of 1,400+ available on InvestingPro, transforming complex data into actionable intelligence.

In other recent news, Acadia Pharmaceuticals reported second-quarter 2026 revenue of approximately $308 million, surpassing the consensus estimate of $296 million. This revenue beat was largely attributed to the strong performance of its Daybue product and steady sales of Nuplazid. RBC Capital, Oppenheimer, and Citizens all raised their price targets for Acadia Pharmaceuticals following the company’s impressive financial results, with RBC Capital and Citizens setting their targets at $37 and $36, respectively, while Oppenheimer increased its target to $25.

RBC Capital and Citizens both maintained an Outperform rating, while Oppenheimer held a Perform rating. Analysts from RBC Capital highlighted Daybue sales of $125 million, which exceeded expectations and were driven by the Stix formulation’s uptake. In addition, H.C. Wainwright reiterated a Buy rating with a $37 price target, noting the completion of enrollment in the Phase 2 RADIANT trial. The trial’s data release is anticipated around September or October, focusing on the primary endpoint SAPS H+D and safety comments. These recent developments reflect positive momentum for Acadia Pharmaceuticals in the market.